Welcome to our dedicated page for Apyx Medical Corporation news (Ticker: APYX), a resource for investors and traders seeking the latest updates and insights on Apyx Medical Corporation stock.
About Apyx Medical Corporation
Apyx Medical Corporation (NASDAQ: APYX) is an advanced energy technology company specializing in the development, manufacturing, and marketing of innovative medical devices for the cosmetic and surgical markets worldwide. With a strong focus on leveraging proprietary technologies, Apyx delivers cutting-edge solutions that elevate surgical precision and aesthetic outcomes.
The company operates through two primary business segments: Advanced Energy and Original Equipment Manufacturing (OEM). Its Advanced Energy segment is centered around its patented Helium Plasma Platform Technology, which is marketed under the Renuvion brand name in the cosmetic surgery market and as J-Plasma in the hospital surgical market. These technologies enable surgeons to achieve unparalleled precision in cutting, coagulation, and ablation of soft tissue while minimizing unintended tissue trauma. The Renuvion system, in particular, empowers plastic surgeons, facial plastic surgeons, and cosmetic physicians to deliver controlled heat to tissue, enhancing patient outcomes in body contouring and other aesthetic procedures.
In addition to its proprietary technologies, Apyx's OEM segment designs, develops, and manufactures electrosurgical generators and related accessories for other medical device manufacturers. This segment leverages the company's decades of expertise in advanced waveforms, allowing it to establish strategic partnerships and diversify its revenue streams.
Industry Position and Market Impact
Apyx Medical Corporation operates at the intersection of the medical device and cosmetic surgery industries, addressing a growing demand for minimally invasive and precise surgical solutions. The company's Renuvion and J-Plasma technologies are supported by extensive clinical validation, with over 90 published clinical documents attesting to their efficacy and safety. This robust evidence base enhances the company's credibility and fosters trust among surgeons and patients alike.
By focusing on innovation and quality, Apyx distinguishes itself in a competitive landscape that includes other advanced energy technology providers. Its ability to address both cosmetic and surgical applications positions it uniquely within its market segments, catering to a diverse customer base that spans hospitals, surgery centers, and private practices.
Commitment to Innovation and Quality
As a company formerly known as Bovie Medical Corporation, Apyx has a legacy of expertise in energy-based medical technologies. Its ongoing commitment to research and development ensures that it remains at the forefront of surgical innovation. By integrating advanced technology with user-centric design, Apyx continues to enhance the capabilities of surgeons and improve patient outcomes.
Conclusion
Apyx Medical Corporation exemplifies the convergence of innovation, precision, and clinical excellence in the medical device industry. Through its proprietary Helium Plasma Platform Technology and strategic OEM partnerships, the company addresses critical needs in both surgical and cosmetic markets. With a focus on delivering transformative solutions and maintaining rigorous quality standards, Apyx is well-positioned to drive meaningful advancements in the field of energy-based medical devices.
Apyx Medical Corporation (NASDAQ: APYX) has received FDA 510(k) clearance for its Renuvion technology, enabling its use in cosmetic procedures aimed at improving lax skin in the neck and chin. Renuvion stands out as the only FDA-cleared solution for this application, providing a minimally-invasive option to address age-related skin sagging. The company anticipates a surge in demand in the cosmetic market, with Renuvion offering effective treatment by directly targeting collagen fibers for a smoother appearance. This development positions Apyx Medical favorably in the growing aesthetic medical field.
Apyx Medical Corporation (NASDAQ:APYX) announced FDA 510(k) clearance for its Renuvion APR Handpiece, allowing use in dermatological procedures for tightening lax skin in the neck and submental areas. This clearance positions Renuvion as the only FDA-cleared device for these applications, targeting an estimated 200,000 neck contouring procedures annually in the U.S. A limited launch is expected by Q3 2022, with full commercialization aimed for year-end. This marks the company's second regulatory clearance within two months, highlighting its commitment to innovative medical solutions.
Apyx Medical Corporation (NASDAQ:APYX) has released positive results from its pivotal Phase II study of the Renuvion device aimed at improving lax skin appearance in the neck and submental area. The study demonstrated key outcomes, with 82.5% of 65 subjects showing improvements at six months, and 96.9% reporting low pain levels post-procedure. Additionally, 85.5% of participants rated their results as improved. No serious adverse events were linked to Renuvion. The company anticipates moving forward with marketing efforts subject to FDA clearance.
Apyx Medical Corporation (NASDAQ:APYX) will release its financial results for Q2 fiscal 2022 on August 11th, after market close. A conference call is scheduled for 5:00 p.m. ET that day, where management will discuss the financial performance and answer questions. Participants can join via phone or a live webcast. Apyx Medical specializes in advanced energy technology, particularly its Helium Plasma Technology products marketed as Renuvion and J-Plasma, used for controlled tissue heating in surgical procedures.
Apyx Medical Corporation (NASDAQ: APYX) announced FDA clearance for its Renuvion Dermal handpiece, allowing for wrinkle reduction procedures in patients with Fitzpatrick skin types I, II, or III. The new treatment, branded as Facial Renewal, offers a nonsurgical method for skin rejuvenation, providing patients with natural-looking results without invasive procedures. According to Dr. Tabasum Mir, the treatment addresses a significant need in cosmetic options. Apyx's President, Charlie Goodwin, highlighted this advancement as a milestone in cosmetic treatments.
Apyx Medical Corporation (NASDAQ:APYX) has received FDA 510(k) clearance for its Renuvion Dermal Handpiece, aimed at treating moderate to severe wrinkles for patients with Fitzpatrick skin types I, II, or III. This milestone allows Apyx to tap into the 200,000 annual U.S. wrinkle reduction procedures. The company plans a limited launch by Q3 2022, with full commercialization anticipated by year-end. CEO Charlie Goodwin highlighted this as a significant achievement for Apyx's long-term strategy in the U.S. cosmetic surgery market.
Apyx Medical Corporation (NASDAQ:APYX), a developer of advanced energy technology and Helium Plasma Technology, announced participation in two upcoming investor conferences. Management will engage in virtual 1x1 meetings at the Craig-Hallum 19th Annual Institutional Investor Conference on June 1, without a formal presentation. They will also take part in a fireside chat at the JMP Securities Life Sciences Conference on June 16 at 9:00 a.m. Eastern Time. An audio webcast of the fireside chat will be available on Apyx's investor relations website.
Apyx Medical Corporation (NASDAQ:APYX) reported a strong financial performance for Q1 2022, with total revenue of $12.5 million, marking a 45% increase year-over-year. The Advanced Energy segment contributed $10.8 million in revenue, a growth of 41%, while OEM revenue surged 72% to $1.7 million. Despite this success, the company reported a net loss of $5.9 million. The outlook for 2022 has been revised to forecast total revenue between $52.5 million and $59.0 million, reflecting growth of 8% to 22%.
Apyx Medical Corporation (NASDAQ:APYX) announced it will release its financial results for Q1 fiscal 2022 on May 12, 2022, before the market opens. Management will host a conference call at 8:00 a.m. ET on the same day to discuss these results and answer questions from investors. Interested parties can join the call by dialing a provided number and using an access code. The results will be available on the company's website.
Apyx Medical Corporation (NASDAQ:APYX) announced the submission of a 510(k) premarket notification to the FDA. This aims to expand indications for the Renuvion APR Handpiece, allowing its use in subcutaneous dermatological and aesthetic procedures to improve lax skin in the neck and submental region. CEO Charlie Goodwin highlighted that this submission aligns with their strategic long-term goals and is backed by safety and effectiveness data from a U.S. IDE clinical study. Successful FDA clearance would enhance market opportunities for Apyx's Renuvion technology.
FAQ
What is the current stock price of Apyx Medical Corporation (APYX)?
What is the market cap of Apyx Medical Corporation (APYX)?
What does Apyx Medical Corporation specialize in?
What are Apyx's primary product offerings?
How does Apyx generate revenue?
What markets does Apyx serve?
What differentiates Apyx from competitors?
What is the Renuvion system used for?
What is the J-Plasma system designed for?
What is Apyx's approach to innovation?
Does Apyx have strategic partnerships?
What is Apyx's legacy in the medical device industry?
